Attendee search 

There is a high unmet need for central nervous system (CNS) diseases in the growing aging population. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. Genervon is bringing GM6, a new clinical-stage drug asset, to regulatory approval and commercialization in China for CNS diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. Most clinical trials for drugs developed through the traditional single-target drug approach have failed to treat the complex neurological disorders that involve multiple interrelated pathways.

GM6 is an innovative first-in-class regulator peptide drug in clinical stage. Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. GM6 is neither an antibody nor a single-target agonist or antagonist. It is a multi-target regulator which simultaneously acts upon multiple extracellular receptors to modulate a series of signaling pathways mediating inflammation and pro-survival responses in both CNS and immune system. Genervon has validated GM6’s target engagement of multiple targets and druggability. GM6 has been de-risked for toxicity in animal studies and safety in three clinical trials. IND documents filed with the FDA can be used to support regulatory filing in China for clinical trials. Genervon is interested to partner through licensing or merger and acquisition. A complete CMC package is ready for technology transfer.

Astrocyte Pharmaceuticals is a preclinical CNS drug development company advancing breakthrough therapeutic agents for treating brain injury patients. Astrocyte is developing the proprietary small molecule pharmaceutical agent AST-004 for acute administration to patients who have suffered a stroke, TBI, or concussion. This product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. Our approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts as we focus on a non-neuronal cell type, the astrocyte, which is the most common cell type in the human brain and has only recently received broader attention as an important cellular target for therapeutic research. The company recently demonstrated AST-004's significant efficacy in an NHP stroke study that mirrors the planned Phase 2 clinical study, and large safety margins in GLP toxicology studies. The company completed its Series A financing in Q4 2020.

CareAcross is a cancer-focused digital health company. Our offerings include personalized digital therapeutics via engaging online platforms. Our business services include real-world evidence, patient engagement & monitoring programs, & clinical trial recruitment.

Our clients include, among others, most of the top biopharma companies in oncology, medical devices companies, diagnostics providers, etc.  Our business services are primarily based on our core assets: direct access to patients, and access to & ownership of patient data. While our focus has been in the cancer therapeutic area through our deep expertise and network, our technology is applicable to any long term or chronic condition, and enables patient engagement and improved outcomes.

Among the outcomes we can share are:

• reduced incidence of side-effects by 11%
• 5x reduction in risk of cancer malnutrition
• 65% increase in physical activity
• 68% improved patient engagement.

The approach is based on scientific evidence & guidelines: CareAcross experts process peer-reviewed journal articles on a daily basis (the company has already analysed several thousands of such articles). The applicable ones are “translated” to lay terms by experienced content writers, continuously updating the content library. The library consists of text, visuals & videos, and currently contains >500,000 words of original, patient-friendly content.
The material is selected based on each patient’s needs as entered in brief questionnaires (built entirely dynamically): advanced dynamic algorithms match each patient’s situation & needs with the right material from the content library. The level of personalisation is so deep that there are modules offering >20,000 different material combinations; the algorithms identify the most relevant for each individual patient.

Additionally, clinicians can monitor patients' progress remotely, and unobtrusively, with intuitive graphs and ongoing data collection.

The current focus areas include comorbidities, side-effects, nutrition, exercise, weight control, emotional wellbeing, and more. Furthermore, and in order to cultivate long-term engagement, CareAcross employs various methodologies including personalised newsletters, notifications, quantified-self techniques with intuitive scores & graphs, and others.
As a result, CareAcross delivers long-term, engaging, personalised coaching services to cancer patients, via material which is always available to them.
The approach does not aim to replace patients’ healthcare teams and clinicians, but to support patients in the majority of their time (95% on average) which they spend outside the clinic.

Our Patient Operations are active in several countries and continents.

Our Chief Medical Officer is a medical oncologist, and has been a president of the European Society for Medical Oncology (ESMO), among others. Our Chief Executive Officer is a member of the Assembly of the European Commission's Cancer Mission.

We have been awarded 3 grants by the European Commission on Big Data and Artificial Intelligence in Cancer enabling international collaborations with established centers of excellence.

We have been profitable in the last 4 accounting periods.